Rakovina Therapeutics to Present New Data at the AACR Annual Meeting 2026 - World's Premier Cancer Research Forum
Rakovina Announces Closing of $1 Million Debenture Unit Private Placement and Debt Settlement Agreements
Rakovina Therapeutics Reports Strong Industry Validation and Emerging Collaborations Following 9th Annual DDR Inhibitors Summit
Rakovina Therapeutics Announces Corporate Update Including up to $1.5 Million in New Financing, Leadership Appointments and Debt Restructuring
Rakovina Therapeutics and Variational AI Expand Collaboration to Advance Next-Generation ATR Inhibitors
Rakovina Therapeutics Management to Attend Partnering Meetings During JPM Week, January in San Francisco, California
Rakovina Therapeutics Announces Three-Month Q3 ended September 30, 2025 Financial Results and Provides Corporate Update
Rakovina Therapeutics Announces Debentureholder Approval of Debenture Extension, Expiry of Warrant Incentive Program
Rakovina Therapeutics Inc. Announces Presentation of Second Abstract at the 2025 Society for Neuro-Oncology Annual Meeting
Rakovina Therapeutics Showcases Compelling Preclinical Data on AI-Discovered CNS-Penetrant ATR/mTOR Inhibitors at the 2025 Society for Neuro-Oncology Annual Meeting
Rakovina Therapeutics' President & CSO to Present and Join Expert Panel at the 9th Annual DDR Inhibitors Summit
Rakovina Therapeutics to Present New Data Highlighting CNS-Penetrant ATR and PARP1 Inhibitors at the 2025 Society for Neuro-Oncology Annual Meeting
Transition Metals Resampling Highlights Broad Gold Intervals at Gowganda Project, Indicating Potential for a Larger Resource Opportunity
Nevada Sunrise Identifies Gold-in-Soil Anomalies over New Target Areas at the Griffon Gold Mine Project, Nevada
